BioTech听Immuncore听has revealed a 拢55 million funding round and has filed for a stock market flotation in the US.听
The听Oxford-based听company delivers biological therapies that have the potential to transform the lives of people with serious diseases听including cancer.听
The Series C funding follows positive Phase 3 trial interim analysis data for听its lead programme听tebentafusp, which听aims to help听patients with metastatic uveal melanoma, a form of eye cancer.听
The听financing,听which听includes听support from existing investors and funds and accounts managed by BlackRock,听will enable听Immunocore听to further expand and accelerate its growing clinical stage pipeline听molecules.听
The company听has听also announced听that it has closed a听拢74m听senior secured loan facility with Oxford Finance LLC, which it听intends to use听in part听to fund a potential commercial launch of听tebentafusp.听
Meanwhile it has hired investment banks Goldman Sachs, JP Morgan and Jefferies to manage a planned listing on the Nasdaq in New York, which it expects to raise 拢74m.听
CEO听Bahija Jallal听said: 鈥淭his successful financing represents another validating milestone for听Immunocore听as we continue our pioneering work in the field of soluble, bispecific TCR immunotherapies to treat a broad range of diseases.听听
鈥�The support of our new and existing investors represents a further endorsement of the potential of our powerful technology platform.听听
鈥�Following the recent positive Phase 3 data for听tebentafusp, we are working to progress this investigational agent through the regulatory process as a potential new treatment to metastatic uveal melanoma patients with a high unmet need.鈥�听
Immunocore听believes听tebentafusp听could be the first new therapy for the treatment of metastatic uveal melanoma in 40 years.听
听